Algernon CEO Christopher Moreau and Consultant Dr. David Nutt Discuss the DMT Stroke Program on BioPub Webcast Hosted by Dr. KSS MD, PhD
Algernon Pharmaceuticals Looks to Highly Regarded UK Company to Conduct Phase 1 DMT Stroke Study
Microdose PsyCap Conference: Investment Opportunities and New Companies in the Sector
Share via
Copy link
Powered by Social Snap